Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 7/20 | 0.41 |
| ▸ | BCHE | P06276 | 6/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.39 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.39 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.39 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923285 | 0.81 | EPHX2 (0.46) | EPHX2ACHEPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL5923376 | 0.81 | EPHX2 (0.49) | EPHX2PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5923243 | 0.80 | MAPT (0.43) | ACHEBCHEPARP1SMN1; SMN2NPC1 | |
| SCHEMBL6514076 | 0.79 | ADORA2A (0.52) | ACHEBCHESMN1; SMN2NPC1RAB9A | |
| SCHEMBL5923387 | 0.78 | ACHE (0.49) | ACHEBCHESMN1; SMN2NPC1RAB9A | |
| SCHEMBL5923374 | 0.77 | EPHX2 (0.45) | EPHX2PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5923299 | 0.76 | EPHX2 (0.46) | EPHX2PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5923119 | 0.76 | HTT (0.48) | EPHX2PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL5923412 | 0.75 | BCHE (0.42) | ACHEBCHESMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL5923235 | 0.75 | KDM4E (0.39) | ACHEBCHESMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2005095345-A2 | HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | EPHX2 3096/4885ACHE 2488/4885BCHE 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.